Market Research Industry Today

Depression -Therapeutics Development in depth with Future Prospects by Leading Key Players: Addex Therapeutics, Albany Molecular Research, FPRT Bio

Depression -Therapeutics Latest Developments by Type, by End-Users/Application, by Region - Forecast and Business Outlook
Published 13 September 2018
Depression - Pipeline Review, H2 2018 is latest pipeline review released by HTF MI to provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, root cause analysis ,mechanism of action (MoA), route of administration (RoA) and molecule type. 

Get Access to Sample PDF @:

If you are want to study the Depression or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Key Players included in the research study are Acadia Pharmaceuticals Inc, Ache Laboratorios Farmaceuticos SA, Adamed Sp z oo, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Albany Molecular Research Inc, Alkermes Plc, Allergan Plc, Amorsa Therapeutics Inc, Anavex Life Sciences Corp, Avanir Pharmaceuticals Inc, Axsome Therapeutics Inc, Azevan Pharmaceuticals Inc, BioCrea GmbH, Bionomics Ltd, BioXcel Therapeutics Inc, Blackthorn Therapeutics Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Calico LLC, Celgene Corp, Cellix Bio Pvt Ltd, Celon Pharma SA, Cerecor Inc, Clera Inc, Delpor Inc, DURECT Corp, Eisai Co Ltd, Eli Lilly and Co, Fabre-Kramer Pharmaceuticals Inc, FPRT Bio Inc, GlaxoSmithKline Plc, GliaCure Inc, H. Lundbeck AS, Heptares Therapeutics Ltd, Impel NeuroPharma Inc, Intas Pharmaceuticals Ltd, IntelGenx Corp, Intra-Cellular Therapies Inc, Jiangsu Nhwa Pharmaceutical Corp Ltd, Johnson & Johnson, Karuna Pharmaceuticals Inc, KemPharm Inc, Kissei Pharmaceutical Co Ltd, Lead Discovery Center GmbH, Les Laboratoires Servier SAS, Lixte Biotechnology Holdings Inc, Luye Pharma Group Ltd, Mapi Pharma Ltd, Mapreg SAS, MedinCell SA, Medlab Clinical Ltd, Meta-IQ ApS, Mitsubishi Tanabe Pharma Corp, Navitor Pharmaceuticals Inc, Neuralstem Inc, Neurocrine Biosciences Inc, NeuroNascent Inc, Nippon Chemiphar Co Ltd, Novartis AG, Omeros Corp, Otsuka Holdings Co Ltd, Pfizer Inc, Pherin Pharmaceuticals Inc, Protagenic Therapeutics Inc, Relmada Therapeutics Inc, Reviva Pharmaceuticals Inc, Richter Gedeon Nyrt, Sage Therapeutics Inc, Shenox Pharmaceuticals LLC, SK Biopharmaceuticals Co Ltd, Sound Pharmaceuticals Inc, Sumitomo Chemical Co Ltd, Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc, Supernus Pharmaceuticals Inc, Syntropharma Ltd, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Co Ltd, Trevena Inc, VistaGen Therapeutics Inc & Zysis Ltd. 

Make inquiry before purchase @ 

The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. 

Depression pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision making capabilities and helps to create effective marketing strategies to gain competitive advantage in health care and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real time basis. 

Buy this research report @ 

Extracts of Chapters from Depression - Pipeline Review, H2 2018 
Chapter 1 , to describe the definition , overview and Therapeutics Development of Depression. 
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes. 
Chapter3, Therapeutics Assessment of Depression by Target, Mechanism of Action, Route of Administration and by Molecule Type. 
Chapter4, to display company profile involved in Therapeutics Development. 
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Depression. 
Chapter 6,7, to describe Depression Appendix, Methodology ,Coverage ,Secondary Research ,Primary Research ,Expert Panel Validation and Contact Us. 

Objective of this study 

- To provides a snapshot of the global therapeutic landscape of Depression. 
- To reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Depression therapeutics and enlists all their major and minor projects. 
- The pipeline guide evaluates Depression therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. 
- The guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Depression 

Reasons to buy 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. 
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
- Find and recognize significant and varied types of therapeutics under development for Depression. 
- Classify potential new clients or partners in the target demographic. 
- Develop tactical initiatives by understanding the focus areas of leading companies. 
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. 
- Formulate corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics. 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 

Early buyers will receive 10% customization on reports. Read Detailed Index of full Research Study at @ 

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. 

Other Industry News

Ready to start publishing

Sign Up today!